NCT05710471View on ClinicalTrials.gov

Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E

PHASE4CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

July 25, 2022

Primary Completion Date

July 25, 2023

Study Completion Date

August 30, 2023

Conditions

Age-Related Macular Degeneration

Interventions

DRUG

Brolucizumab

Intravitreal injection

DRUG

Aflibercept

Intravitreal injection

Trial Locations (1)

Unknown

Grantham Hospital, Hong Kong

All Listed Sponsors

lead

The University of Hong Kong

OTHER